3 of 100
BACKNEXT
3. Hi-Tech Pharmacal
3-year average
Revenue Growth: 51%
Profit Growth: 234%
Total Return: 42%
This maker of generic drugs for allergies, diabetes and pain reported 51% sales gains in 2010 and has continued strong this year with a 45% year-over-year increase in the most recent quarter. The company-which specializes in liquid and spray drugs and makes a popular generic version of the allergy medication Flonase-seems poised for continued growth: It currently has 13 pending generics applications at the Food & Drug Adminstration, addressing more than $1 billion in name-brand drug sales in 2010, according to IMS Health. Besides its generics division, Hi-Tech has two other segments: The health care products division sells branded over-the-counter products. And a line of magnesium supplements, acquired in 2010, has also contributed to sales.
Get stock quote: HITK
Revenue ($ millions): $190.9
Net Income ($ millions): $41.5
Industry: Health Care
Network with Hi-Tech Pharmacal
From the September 26, 2011 issue.
Revenue and profit figures reflect the four quarters ended on or before April 30,2011.
Total return is through June 30, 2011.

Green Plains Renewable Energy 299%
SXC Health Solutions 151%
Discovery Communications 105%
Sturm Ruger & Co 848%
Cirrus Logic 340%
Hi-Tech Pharmacal 234%
Green Mountain Coffee Roasters 120%
Netflix 116%
Acme Packet 108%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More